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Objective/Background: With the introduction of novel molecular techniques that rely on
rifampicin (RIF) susceptibility, resistance to isoniazid (INH) or other first-line drugs remains
undetected. Such patients are prescribed first-line antituberculosis therapy and are on RIF
monodrug therapy during the continuation phase, which may lead to therapeutic failure
and emergence of multidrug resistance. We aimed to study INH resistance among
RIF-susceptible Mycobacterium tuberculosis (MTB) isolates from retreatment patients.
Methods: The Drug Susceptibility Testing data for four first-line drugs (streptomycin [SM],
INH, RIF, and ethambutol [EMB]) using BACTEC MGIT 960 (Becton Dickinson, Franklin 124
Lakes, NJ ,USA) and for two drugs (INH and RIF) using line probe assay was analyzed
retrospectively at the Department of Microbiology, National Institute of Tuberculosis and
Respiratory Diseases (New Delhi, India).
Results: We analyzed 4910 drug susceptibility results performed using the BACTEC MGIT960
liquid culture system from 2009 to 2015. We found that 969 (19.7%) isolates were sensitive to
all four first-line drugs, 3941 (80.3%) isolates were resistant to one or more drugs, and 3041
(61.9%) isolates were resistant to both RIF and INH with or without resistance to any other
drug (multidrug resistant). Monodrug resistance to SM and EMB was observed in 94 (1.9%)
and 8 (0.16%) isolates, respectively. RIF resistance without INH resistance was observed in
22 (0.44%) isolates. There were 776 isolates sensitive to RIF, but resistant to INH. Among
these, INH resistance with EMB and/or SM was observed in 367 (7.47%) isolates, whereas
409 (8.3%) isolates were resistant to INH alone. The results of line probe assay from 2012
to 2015 were also analyzed, and the resistance to INH alone among all isolates with valid
results was found to be 9.32% (1462/15,676). More than 75% of these isolates harbor
mutations in the kat G gene associated with high-level resistance.rom tuber-
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culosis patients. Int. J. Mycobacteriol. (2016),Conclusion: INH resistance among RIF-susceptible isolates was present in 10–15% of the
total cases. Among these cases, the use of RIF susceptibility alone will fail to detect INH
resistance. Since higher rates of failure, relapse, or acquired resistance are linked with
INH resistance, rollout of techniques focusing on RIF resistance must, therefore, be accom-
panied by strict monitoring for better management of patients.Conflicts of interest
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